

# Satellite Symposia

Status as of 1 May 2018



WEDNESDAY, 13 JUNE 2018

18:15-19:45

Hall 3

Vindico Medical Education supported by  
Bristol-Myers Squibb

## Rheumatic complications of cancer immunotherapy: a new and emerging field in rheumatology

### Chair(s):

Leonard H. Calabrese (United States)  
Jan Leipe (Germany)  
Xavier Mariette (France)

Introduction and pre-test	18:15
Biology of T cell exhaustion and the evolution of immune checkpoint inhibitors	18:25
Diagnosis and management of rheumatic irAEs from cancer immunotherapy	18:50
Clinical cases	19:15
Post-test and question and answer	19:35

18:15-19:45

Auditorium

### AbbVie

## RA treatment beyond the conventional: will JAK inhibitors disrupt our treatment paradigms?

### Chair(s):

Peter Nash (Australia)

**Peter Nash (Australia)** 18:15  
Welcome and introduction

**John Isaacs (United Kingdom)** 18:25  
Influencing the JAK pathway: does selective inhibition make mechanistic sense?

**Andrea Rubbert-Roth (Germany)** 18:40  
Beyond methotrexate: the role of JAK inhibitors when csDMARDs fail

**Peter Nash (Australia)** 19:00  
Beyond biologics: JAK inhibitors as a novel alternative in bDMARD-IR patients

**All** 19:20  
Panel discussion and Q&A

18:15-19:45

Elicium 2

### Pfizer

## Evolution or Revolution? How JAK inhibitors are changing the standard of care in RA

### Chair(s):

Ronald van Vollenhoven (Netherlands)

**Ronald van Vollenhoven (Netherlands)** 18:15  
Welcome and introductions  
Where we are today: treatment trends in RA from the clinician's perspective

**Eduardo Mysler (Argentina)** 18:25  
Proactive search: the best treatment for each patient

**Ernest Choy (United Kingdom)** 18:50  
JAK inhibitors: novel therapies offering efficacious options for patients with RA

**Torsten Witte (Germany)** 19:15  
Safety and real-world data offer a wider window into advanced therapies for patients with RA

**Ronald van Vollenhoven (Netherlands)** 19:40  
RA therapy tomorrow: the road ahead

18:15-19:45

Hall 7.2

**GSK****Leading the way towards a holistic approach to managing SLE****Chair:**

Munther Khamashta (United Arab Emirates)

**Munther Khamashta (United Arab Emirates) 18:15**  
Welcome and introduction**Munther Khamashta (United Arab Emirates) 18:18**  
Patient and physician priorities in SLE management**Marta Mosca (Italy) 18:30**  
Why we shouldn't be tired of hearing about fatigue**Alexandre Voskuyl (Netherlands) 19:00**  
Reducing long-term organ damage: Are we shooting for the moon?**Munther Khamashta (United Arab Emirates) 19:30**  
Summing up and concluding remarks

## Forum

**Celltrion Healthcare****REdefining the future with InfixiMab bioSIMilAr****Chair(s):**

Rieke Alten (Germany)

**Rieke Alten (Germany) 18:15**  
Welcome and introduction**Laurent Grange (France) 18:20**  
Perspectives on living with rheumatic diseases**Rieke Alten (Germany) 18:35**  
Physicians' perspective on early introduction of biologics**Ki Chul Shin (Republic of Korea) 18:50**  
Drug retention of infliximab in ankylosing spondylitis: data from KOBIO**Rene Westhovens (Belgium) 19:05**  
Future of infliximab: introduction of the subcutaneous formulation**All 19:20**  
Panel discussion

18:15-19:45

Emerald

**UCB****The reality of risk – how are we responding to fragility fracture in rheumatology?****Chair(s):**

Socrates Papapoulos (Netherlands)

**Socrates Papapoulos (Netherlands) 18:15**  
Why should we be vigilant for fragility fracture?**Ian Bruce (United Kingdom) 18:30**  
**Ivo Vlaev (United Kingdom)**

What are the complexities of decisions facing the rheumatologist? Clinical and behavioural perspectives

**Ian Bruce (United Kingdom) 18:50****Socrates Papapoulos (Netherlands)**  
Improving the odds in fragility fracture: how can we act on risk factors in the rheumatology consultation?**Ivo Vlaev (United Kingdom) 19:10**

How does our perception of risk influence how we make decisions in the rheumatology clinic?

**Socrates Papapoulos (Netherlands) 19:20**

Collaborative care in fragility fracture: recommendations for risk assessment and referral

**All 19:30**

Audience Q&amp;A

18:15-19:45

E106/E107

**IBSA****The treatment of OA: new concepts for an 'old' disease****Chair(s):**

Cem Gabay (Switzerland)

**Cem Gabay (Switzerland) 18:15**  
Welcome and introduction**Xavier Chevalier (France) 18:20**

Treat to target in osteoarthritis: towards a better benefit/risk ratio of oral drugs

**Cem Gabay (Switzerland) 18:40**

Osteoarthritis of the hand: current evidence on its management

**Jean Dudler (Switzerland) 19:00**

Additional analysis on CONCEPT study data

**Chiara Schiraldi (Italy) 19:15**

Pharmaceutical-grade chondroitin sulphate vs food supplements: are they equivalent?

**All 19:30**

Question and answer session

**Cem Gabay (Switzerland) 19:40**

Concluding remarks

THURSDAY, 14 JUNE 2018

08:15-09:45

Hall 3

**AbbVie****Transforming developments: the dynamic face of rheumatology****Chair(s):**

Ferry Breedveld (Netherlands)

**Ferry Breedveld (Netherlands)**

08:15

Welcome and introduction

Transforming treatments: how TNF inhibitors led the field in the biologic revolution

**Boulos Haraoui (Canada)**

08:30

Transforming standards: treat to target and the PASSIONate revolution

**Wouter Bos (Netherlands)**

08:45

Transforming outcomes: the role of patients in assessing their own disease

**Lisa Olson (United States)**

09:05

Transforming targets: drug discovery and development

**All**

09:25

Panel discussion and Q&amp;A

08:15-09:45

Auditorium

**Novartis****Making the invisible visible: the impact of IL-17A inhibition in psoriatic arthritis****Chair(s):**

Dafna Gladman (Canada)

**Dafna Gladman (Canada)**

08:15

Welcome and introductions

**Georg Schett (Germany)**

08:20

Enthesitis: the link between the skin and joints in PsA

**Laura Coates (United Kingdom)**

08:40

A 360 overview on the evolving unmet needs in PsA

**Philip Conaghan (United Kingdom)**

08:55

Insights into PsA from modern imaging

**Philip Mease (United States)**

09:10

GRAPPA treatment recommendations: are they met with IL-17A inhibition?

**All**

09:30

Panel discussion and conclusions

08:15-09:45

Elicium 2

**Lilly****IL-17A inhibition: optimising the PsA management****Chair(s):**

Michael Nurmohamed (Netherlands)

**Michael Nurmohamed (Netherlands)**

08:15

Welcome and introduction

**Helena Marzo-Ortega (United Kingdom)**

08:20

Is the management of patients with PsA optimal?

**Frank Behrens (Germany)**

08:35

Overview of ixekizumab benefits and safety results

**Diamant Thaçi (Germany)**

08:50

**Peter Nash (Australia)**

PsA management in the real world: the rheumatologist and dermatologist perspective

**All**

09:20

Panel discussion

**Michael Nurmohamed (Netherlands)**

09:30

Summary and symposium close

08:15-09:45

Hall 7.2

**Roche****Journey from clinical trials to patient care****Chair(s):**

Ernest Choy (United Kingdom)

**Ernest Choy (United Kingdom)**

08:15

Welcome &amp; introduction

**Ernest Choy (United Kingdom)**

08:20

Exploring the value of real-world evidence (RWE)

**Deborah Symmons (United Kingdom)**

08:30

Confidence in treating the at-risk and elderly population

**Fabrizio de Benedetti (Italy)**

08:50

Advancing knowledge of the paediatric population

**Frank Buttgereit (Germany)**

09:10

Optimising the use of glucocorticoids in clinical practice

**Ernest Choy (United Kingdom)**

09:30

Summary

**All Faculty**

09:35

Question &amp; answer session

**08:15-09:45 Forum**

**Biogen**

**Anti-TNF in rheumatic diseases: inventory and outlook**

**Chair(s):**

Peter Taylor (United Kingdom)

**Peter Taylor (United Kingdom) 08:15**

Opening, intro & overview: the treatment landscape in RA

Short presentations integrated at various time points into an interactive faculty/audience discussion

**Raj Sengupta (United Kingdom)**

Preparing a switch: the perfect time to re-evaluate the clinical status of patients with RA/AS

**Paul Enck (Germany)**

Preparing a switch: the perfect time to re-evaluate the patient's psychosocial status

**Juergen Braun (Germany)**

Successful switching: shared decision making with the patient is critical

**Glenn Haugeberg (Norway)**

Post-switch patient follow-up in busy daily clinical practice - opportunities and challenges of remote patient monitoring

**All 09:40**

Summary and conclusion

**08:15-09:45 Amtrium**

**medac**

**Methotrexate – new insights into the anchor drug**

**Chair(s):**

Daniel Aletaha (Austria)

**Daniel Aletaha (Austria)**

Benefits of subcutaneous MTX in daily practice

**Jens Thiel (Germany)**

Relevance of the microbiome for RA treatment outcomes

**Ronald van Vollenhoven (Netherlands)**

JAK-inhibitors: will they change the treatment paradigm?

**Ivan Foeldvari (Germany)**

How to optimize JIA treatment

**08:15-09:45 Emerald**

**Menarini**

**Multimodal approach for acute pain in rheumatology - a new paradigm targeting multiple mechanisms**

**Chair(s):**

Serge Perrot (France)

**Serge Perrot (France) 08:15**

Introduction

**Stefano Coaccioli (Italy) 08:30**

Low back pain and osteoarthritis: from clinical features to complex mechanisms

**Serge Perrot (France) 08:50**

Multimodal approach, a step forward in the current therapeutic strategy

**Magdi Hanna (United Kingdom) 09:10**

Rationale of the new oral fixed dose combination of dexketoprofen/Tramadol in targeting multiple mechanisms of moderate to severe acute pain

**Discussion and final remarks 09:30**

**08:15-09:45 E106/E107**

**Amgen**

**Ready for the next biosimilar? Key stakeholder insights to guide choice**

**Chair(s):**

Thierry Thomas (France)

Fernando Pérez-Ruiz (Spain)

**Thierry Thomas (France) 08:15**

Welcome and introduction

**Murray Aitken (United States) 08:25**

Assessing biosimilar uptake and use: a marketplace evaluation

**Fernando Pérez-Ruiz (Spain) 08:45**

Clinical perspectives: what to consider when selecting the next anti-TNF biosimilar

**Alison Kent (United Kingdom) 09:10**

Patient perspectives on anti-TNF biosimilars: understanding attitudes, beliefs and expectations

**All 09:30**

Panel discussion

**Fernando Pérez-Ruiz (Spain) 09:40**

Closing remarks

**17:30-19:00 Auditorium****AbbVie****Solving the patient puzzle: a pragmatic approach to SpA management****Chair(s):**

Georg Schett (Germany)

**Georg Schett (Germany) 17:30**

Welcome and introduction

The many faces of SpA: how does inflammation lead to multifaceted disease?

**Denis Poddubnyy (Germany) 17:45**

Disease progression: under control or still a cause for concern?

**Philip Mease (United States) 18:05**

Optimising long-term treatment: lessons from clinical practice

**Dirk Elewaut (Belgium) 18:25**

Integrated care: a practical approach to patient management

**All 18:45**

Panel discussion and Q&amp;A

**17:30-19:00 Hall 7.2****Pfizer****How to detect and treat unresolved symptoms in the patient with psoriatic arthritis****Chair(s):**

Désirée van der Heijde (Netherlands)

**Désirée van der Heijde (Netherlands) 17:30**

Welcome and introductions

**Laure Gossec (France) 17:35**

Diagnostic 'hot spots': defining targets, detecting patients' symptoms

**Enrique Soriano (Argentina) 17:55**

New products, new opportunities in PsA

**Frank Behrens (Germany) 18:20**

Optimising treatments: the physician and nurse practitioner partnership

**Désirée van der Heijde (Netherlands) 18:40**

Audience Q&amp;A/panel discussion summary and close

**17:30-19:00 Forum****Sanofi Genzyme****The challenges of multi-morbidities in RA: IL-6 and chronic inflammation****Chair(s):**

Peter Taylor (United Kingdom)

**Peter Taylor (United Kingdom) 17:30**

Meeting the challenge of multi-morbidities in RA

**Michael Nurmohamed (Netherlands) 17:40**

Multi-morbidities associated with RA: defining the systemic manifestations of the disease

**Ernest Choy (United Kingdom) 17:55**

The multi-faceted role of IL-6 in RA and other RA-associated conditions

**Mark Genovese (United States) 18:15**

The effects of IL-6R blockade inside and outside the RA joint

**All 18:35**

Moderated discussion with faculty and audience Q&amp;A

**Peter Taylor (United Kingdom) 18:55**

Close

**17:30-19:00 Amtrium****Janssen****A practical guide to new treatments in psoriatic arthritis and psoriasis****Chair(s):**

Dennis McGonagle (United Kingdom)

Costantino Pitzalis (United Kingdom)

**Dennis McGonagle (United Kingdom) 17:30****Costantino Pitzalis (United Kingdom)**

Welcome and introduction

**Costantino Pitzalis (United Kingdom) 17:35**

Pathophysiology of joint and skin diseases and implications for treatment

**Lluis Puig (Spain) 17:55**

Lessons from the skin: therapeutic options for psoriasis in clinical practice

**Dennis McGonagle (United Kingdom) 18:20**

Lessons from the joint: therapeutic options for psoriatic arthritis in clinical practice

**All 18:45**

Q&amp;A

**Conclusions and close of meeting 18:55**

**17:30-19:00 Emerald**

**Bristol-Myers Squibb**  
**Modulating the wayward T cell: the new horizon in autoimmunity and cancer**

**Chair(s):**  
Leonard Calabrese (United States)

<b>Leonard Calabrese (United States)</b>	<b>17:45</b>
Welcome and introduction	
<b>Leonard Calabrese (United States)</b>	<b>17:47</b>
T-cell co-stimulation in health and disease	
<b>Roberto Caporali (Italy)</b>	<b>18:12</b>
T cell-B cell communication in autoimmune diseases, with a focus on RA	
<b>Christian Blank (Netherlands)</b>	<b>18:37</b>
Expanding our understanding of T-cell modulation through learnings from cancer	
<b>All</b>	<b>19:02</b>
Panel discussion and Q&A	

**17:30-19:00 E106/E107**

**Samsung Bioepis**  
**The era of biosimilars: reshaping the healthcare environment**

**Chair(s):**  
Josef Smolen (Austria)

<b>Josef Smolen (Austria)</b>	<b>17:30</b>
Welcome and introduction	
<b>Josef Smolen (Austria)</b>	<b>17:40</b>
Anti-TNF biosimilars in rheumatology	
<b>João Gonçalves (Portugal)</b>	<b>17:55</b>
Reinvestigating biologics quality excellence	
<b>Mark Quinn (United Kingdom)</b>	<b>18:10</b>
Biosimilar adoption: improving rheumatology services for patients	
<b>Fabrizio Benedetti (Italy)</b>	<b>18:25</b>
Understanding the nocebo effect	
<b>All</b>	<b>18:40</b>
Q&A	
<b>Josef Smolen (Austria)</b>	<b>18:50</b>
Closing	

**FRIDAY, 15 JUNE 2018**

**08:15-09:45 Auditorium**

**Lilly**  
**Challenging the rheumatoid arthritis treatment standards with JAK inhibitors**

**Chair(s):**  
Désirée van der Heijde (Netherlands), Mark C. Genovese (United States)

<b>Désirée van der Heijde (Netherlands)</b>	<b>08:15</b>
<b>Mark C. Genovese (United States)</b>	
Welcome and introduction	
<b>Peter Taylor (United Kingdom)</b>	<b>08:20</b>
JAK inhibitors - are they all the same?	
<b>Paul Emery (United Kingdom)</b>	<b>08:35</b>
JAK inhibitor baricitinib: how is it different from the standard of care (anti-TNF)?	
<b>Ronald van Vollenhoven (Netherlands)</b>	<b>08:50</b>
JAK inhibitors position in the treatment algorithm of rheumatoid arthritis	
<b>Ulf Müller-Ladner (Germany)</b>	<b>09:05</b>
JAK inhibitors in clinical practice	
<b>Désirée van der Heijde (Netherlands)</b>	<b>09:20</b>
<b>Mark C. Genovese (United States)</b>	
Panel discussion and Q&A	
<b>Symposium close</b>	<b>09:45</b>

**08:15-09:45 Elicium 2**

**Novartis**  
**IL-17A inhibition in axial spondyloarthritis: new insights and implications for clinical practice**

**Chair(s):**  
Filip van den Bosch (Belgium)

<b>Filip van den Bosch (Belgium)</b>	<b>08:15</b>
Welcome and introductions	
<b>Filip van den Bosch (Belgium)</b>	<b>08:20</b>
Axial spondyloarthritis: what matters to a patient?	
<b>Atul Deodhar (United States)</b>	<b>08:35</b>
Clinical intervention in axial spondyloarthritis: why, when and how?	
<b>Rik Lories (Belgium)</b>	<b>08:55</b>
Underlying pathophysiology of axial spondyloarthritis: clinical assessments and implications	
<b>Xenofon Baraliakos (Germany)</b>	<b>09:10</b>
IL-17A inhibition in axial spondyloarthritis: current and future perspectives	
<b>All</b>	<b>09:30</b>
Panel discussion and conclusions	



**08:15-09:45 Forum****Integritas supported by Gilead Sciences, Inc.****Clinical issues in rheumatoid arthritis: discussions and debates on the evolving roles of targeted synthetic DMARDs****Chair(s):**

Rieke Alten (Germany)

**Rieke Alten (Germany) 08:15**

Welcome and pre-activity questionnaire

**Josef Smolen (Austria) 08:20**

Pathophysiology: a focus on JAK enzymes

**Joel Kremer (United States) 08:35**

Long-term assessment of patient with RA: understanding treatment targets as a foundation for therapeutic tailoring

**Rieke Alten (Germany) 08:55**

Targeted synthetic DMARDs in the treatment of RA

**All 09:15**

Case study panel discussion: putting the evidence to practice

**All 09:30**

Post-activity questionnaire and Q&amp;A session

**08:15-09:45 Amtrium****UCB****Axial spondyloarthritis in 2018: new data, less compromise?****Chair(s):**

Martin Rudwaleit (Germany)

**Martin Rudwaleit (Germany) 08:15**

Welcome and introduction from the symposium chair

**Lianne Gensler (United States) 08:20**

Diagnostic delay, establishing disease control and starting a family

**Maxime Dougados (France) 08:45**

The right management strategy for the right patient

**Denis Poddubnyy (Germany) 09:05**

Taking control of structural damage progression and exploring new horizons

**Martin Rudwaleit (Germany) 09:25**

Wrap-up and conclusion

**All 09:40**

Question and answer session moderated by the symposium chair

**08:15-09:45 Emerald****Celgene****Towards a targeted approach in psoriatic arthritis with PDE4 inhibition****Chair(s):**

Laure Gossec (France)

**Laure Gossec (France) 08:15**

Opening statement

**Laure Gossec (France) 08:20**

Guidelines in evolution and their applicability in treatment decisions

**Frank Behrens (Germany) 08:35**

Evidence from homogeneous clinical trials for a diverse patient population – the challenge in PsA patient care

**Philip J. Mease (United States) 09:00**Optimising the clinical utility of PDE4 inhibition  
Audience Q&A**Laure Gossec (France) 09:20**

Summary and close

**08:15-09:45 E106/E107****Boehringer Ingelheim****Interstitial lung disease in autoimmune rheumatic diseases – moving towards better patient care****Chair(s):**

Frank van den Hoogen (Netherlands)

**Frank van den Hoogen (Netherlands) 08:15**

How relevant is ILD in autoimmune rheumatic diseases?

**Athol Wells (United Kingdom) 08:25**

How should we diagnose and monitor ILD?

**Christopher Denton (United Kingdom) 08:45**

Treatment of ILD in autoimmune rheumatic diseases

**Jörg Distler (Germany) 09:05**

Future perspectives on the treatment of fibrosis

**All 09:25**

Questions and answers

17:30-19:00

Auditorium

**Pfizer****Unraveling chronic pain: from defining to modulating****Chair(s):**

Francis Berenbaum (France)

**Francis Berenbaum (France)**

17:30

Welcome and faculty introductions

**Francis Berenbaum (France)**

17:35

Defining the humanistic and societal burden of chronic pain

**Martin Koltzenburg (United Kingdom)**

17:55

Overview of pain pathways and mediators of pain sensitization

**Richard Langford (United Kingdom)**

18:20

Current and future approaches to modulate chronic pain

**All**

18:45

Panel discussion and Q&amp;A

**Francis Berenbaum (France)**

18:55

Closing remarks

17:30-19:00

Forum

**RMEI supported by Sanofi Genzyme & Regeneron****Global perspectives in RA: the role of new biologics for optimal management****Chair(s):**

Paul Emery (United Kingdom)

**Speakers:**

Paul Emery (United Kingdom)

Leonard H. Calabrese (United States)

Josef F. Smolen (Austria)

**Paul Emery (United Kingdom)**

17:30

Introductions and overview of panel topics

**Faculty Panel Discussion #1**

17:40

The patient with RA who fails to respond

**Faculty Panel Discussion #2**

18:05

The patient with RA who becomes non-responsive

**Faculty Panel Discussion #3**

18:30

The patient with poor response and comorbidities

**Paul Emery (United Kingdom)**

18:55

Summary remarks

17:30-19:00

Amtrium

**Rheumatology Today****Highlights of EULAR 2018****Chair(s):**

Matthias Schneider (Germany)

**Speakers:**

Peer M. Aries (Germany)

Xenofon Baraliakos (Germany)

Frank Behrens (Germany)

Christof Iking-Konert (Germany)

Christof Specker (Germany)

Torsten Witte (Germany)

**Round table experts:**

Frank Buttgereit (Germany)

Jens Gert Kuipers (Germany)

Ulf Müller-Ladner (Germany)

Presentation of six trials presented at EULAR 2018 featuring the following topics:

- Axial spondylarthritis
- Biologica monotherapy
- Collagenoses
- Novelities in RA treatment
- Psoriatic arthritis
- Vasculitis

17:30-19:00

Emerald

**Janssen****Lupus: now and in the future****Chair(s):**

David Isenberg (United Kingdom)

Ronald van Vollenhoven (Netherlands)

**David Isenberg (United Kingdom)**

17:30

**Angela Tincani (Italy)**

Welcome and introduction

**Eisabet Svenungsson (Sweden)**

17:40

Current options: limitations of current treatment in lupus

**Ronald van Vollenhoven (Netherlands)**

18:00

How to assess lupus in clinical care

**David Isenberg (United Kingdom)**

18:20

Biologics: what's coming next?

**David Isenberg (United Kingdom)**

18:40

**Elisabet Svenungsson (Sweden)****Angela Tincani (Italy)****Ronald van Vollenhoven (Netherlands)**

Panel discussion

**Angela Tincani (Italy)**

18:55

**Ronald van Vollenhoven (Netherlands)**

Conclusions and close of meeting



17:30-19:00

E106/E107

**Menarini****Hyperuricemia with deposition:  
a multisystemic disease****Chair(s):**

Fernando Perez-Ruiz (Spain)

**Fernando Perez-Ruiz (Spain)**

Introduction

**Claudio Borghi (Italy)**

Hyperuricemia with deposition: a cardio metabolic disorder

**Leonardo Punzi**

Interaction between hyperuricemia with deposition and rheumatic diseases

**Fernando Perez-Ruiz (Spain)**

Hyperuricemia with deposition: the importance of adherence to treatment

**Fernando Perez-Ruiz (Spain)**

Summary and meeting close